Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 61,265 Shares

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Director Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Karimah Es Sabar also recently made the following trade(s):

• On Wednesday, April 1st, Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.03, for a total transaction of $1,667,397.05.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $32.11 on Friday. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -14.21 and a beta of 0.48. Capricor Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $40.37. The business’s fifty day moving average price is $27.20 and its 200-day moving average price is $18.83.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). Equities research analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new position in shares of Capricor Therapeutics in the third quarter worth approximately $1,555,000. Geode Capital Management LLC raised its position in shares of Capricor Therapeutics by 6.8% during the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock valued at $9,565,000 after purchasing an additional 61,701 shares during the period. HBK Sorce Advisory LLC lifted its stake in shares of Capricor Therapeutics by 33.7% during the 3rd quarter. HBK Sorce Advisory LLC now owns 170,577 shares of the biotechnology company’s stock valued at $1,141,000 after buying an additional 42,951 shares in the last quarter. Pier Capital LLC boosted its holdings in Capricor Therapeutics by 35.0% in the 3rd quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock worth $3,580,000 after buying an additional 128,837 shares during the period. Finally, First Financial Bank Trust Division bought a new position in Capricor Therapeutics in the 3rd quarter worth $203,000. Institutional investors own 21.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on CAPR shares. Maxim Group raised their price objective on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Wall Street Zen downgraded shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research note on Friday, March 13th. B. Riley Financial boosted their price objective on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Finally, Oppenheimer upped their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $46.09.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.